Original Article

Evaluation of hospital blood culture utilization rates to identify opportunities for diagnostic stewardship

Bobby G. Warren MPS^{1,2} (D. Michael E. Yarrington MD^{1,2} (D. Christopher R. Polage MD^{1,2,3},

Deverick J. Anderson $MD^{1,2}$ and Rebekah W. Moehring MD^{1,2}

¹Duke Center for Antimicrobial Stewardship and Infection Prevention, Durham, North Carolina, ²Division of Infectious Diseases, Duke University Medical Center, Durham, North Carolina and ³Department of Pathology, Duke University School of Medicine, Durham, North Carolina

Abstract

Objectives: To evaluate the pattern of blood-culture utilization among a cohort of 6 hospitals to identify potential opportunities for diagnostic stewardship.

Methods: We completed a retrospective analysis of blood-culture utilization during adult inpatient or emergency department (ED) encounters in 6 hospitals from May 2019 to April 2020. We investigated 2 measures of blood-culture utilization rates (BCURs): the total number of blood cultures, defined as a unique accession number per 1,000 patient days (BCX) and a new metric of blood-culture events per 1,000 patient days to account for paired culture practices. We defined a blood-culture event as an initial blood culture and all subsequent samples for culture drawn within 12 hours for patients with an inpatient or ED encounter. Cultures were evaluated by unit type, positivity and contamination rates, and other markers evaluating the quality of blood-culture collection.

Results: In total, 111,520 blood cultures, 52,550 blood culture events, 165,456 inpatient admissions, and 568,928 patient days were analyzed. Overall, the mean BCUR was 196 blood cultures per 1,000 patient days, with 92 blood culture events per 1,000 patient days (range, 64–155 among hospitals). Furthermore, 7% of blood-culture events were single culture events, 55% began in the ED, and 77% occurred in the first 3 hospital days. Among all blood cultures, 7.7% grew a likely pathogen, 2.1% were contaminated, and 5.9% of first blood cultures were collected after the initiation of antibiotics.

Conclusions: Blood-culture utilization varied by hospital and was heavily influenced by ED culture volumes. Hospital comparisons of bloodculture metrics can assist in identifying opportunities to optimize blood-culture collection practices.

(Received 27 January 2022; accepted 20 April 2022; electronically published 8 August 2022)

Blood cultures are an important clinical diagnostic test used to identify bacteremia and guide treatment decisions.^{[1](#page-4-0)} However, inappropriate blood-culture collection techniques and overtesting can cause harm and excess use of healthcare resources and may result in misdiagnosis. For example, blood-culture contamination events lead to prolonged hospitalization, excess use of laboratory resources, misdiagnosis of central-line–associated bacteremia (CLABSI), and empiric use of high-risk antibiotics such as vancomycin[2](#page-4-0) Historically, determining which patients are at high risk for developing bacteremia has been difficult, and clinicians generally have a low threshold for ordering blood cultures as part of routine care, particularly since the Centers for Medicare and Medicaid SEP-1 Core Measure was put into practice. $3-5$ $3-5$ Optimizing the use of blood cultures is crucial for the detection of bacteremia while reducing overuse of antibiotic therapy or other potential harms.^{[2](#page-4-0)} Few studies have quantified utilization rates and, of those that have, many are limited to a specific patient population.^{[1,6](#page-4-0)-[9](#page-4-0)} Additionally, existing expert consensus recommendations do not include

Author for correspondence: Bobby Warren, E-mail: bobby.warren@duke.edu

Cite this article: Warren BG, et al. (2023). Evaluation of hospital blood culture utilization rates to identify opportunities for diagnostic stewardship. Infection Control & Hospital Epidemiology, 44: 200–205, <https://doi.org/10.1017/ice.2022.191>

recommendations for when blood cultures should be obtained nor are they widely used or based on strong evidence. As a result, few hospitals routinely analyze blood-culturing practices as an area for improvement.^{[8](#page-4-0)} In this study, we aimed (1) to pilot test different blood-culture utilization metrics to identify opportunities for diagnostic stewardship among 6 hospitals and (2) to provide hospital comparisons that could contribute to hypothesis generation in future targeted studies.

Methods

Study population

We performed a multicenter retrospective analysis of bloodculture utilization in a limited data set previously collected for a clinical trial at 6 hospitals in the southeastern United States.^{[10](#page-4-0)} Study sites included 1 large, academic, medical center (hospital A) and 5 community hospitals (B–F) from May 2019 to April 2020. Analyses included unique sets of blood cultures drawn during inpatient or emergency department (ED) encounters as designated by National Healthcare Safety Network (NHSN) unit mapping.^{[11](#page-5-0)} Only the academic medical center reported blood cultures from pediatric patients, the majority of which were single

© The Author(s), 2022. Published by Cambridge University Press on behalf of The Society for Healthcare Epidemiology of America.

Fig. 1. Blood-culture utilization rate by hospital.

i
■ Events Per 1,000 Patient Days

cultures, in contrast with paired culturing practice in adults (Supplementary Fig. [1](https://doi.org/10.1017/ice.2022.191) online). As a result, we excluded patients <18 years of age from hospital-level analyses. This exclusion affected 11% of total blood-culture events (range, 0%–19% per hospital). We excluded cultures drawn in procedural or outpatient areas as well as those with unmapped collection locations.

Outcomes

We investigated 2 measures of blood-culture utilization. First, the hospital-level blood-culture utilization rate (BCUR) was defined as the total number of blood-culture sets per 1,000 patient days (BCX), a previously recommended metric. $2,4-6$ $2,4-6$ $2,4-6$ We defined a BCX by unique laboratory accession number, which we interpreted as a set of at least 1 anaerobic and 1–2 aerobic bottles procured through a single venipuncture or during 1 catheter draw.

Second, we developed and evaluated a new metric of BCUR defined as blood-culture events per 1,000 patient days (BCE). We aimed to better differentiate single-culture events (in which only a single blood-culture set was drawn), which is discouraged as a practice due to reduced yield as well as difficulty in interpretation of contaminants. We defined a blood-culture event as an initial blood-culture set and all subsequent blood-culture sets drawn within 12 hours of the initial collection time. We included patients with an inpatient or ED encounter.

Both metrics were used to describe utilization by unit, day of the week, month, and age group. We measured blood-culture events per admission, blood-culture events with only a single culture set, the percentage of blood-culture events that began in the ED, and the proportion of inpatient admissions with a blood-culture event. At the blood-culture set level, we measured the number of blood cultures collected after the initiation of antibiotics, the number of follow-up blood-culture sets collected after the initiation of antibiotics, and the percentage of blood-culture sets that were positive or contaminated with common skin commensals.

Definitions

We defined patient days, inpatient locations, and unit-type per NHSN methods.[12](#page-5-0) We limited hospital-level utilization estimates to exclude procedural, operating, and perioperative, behavioral, rehabilitation, and psychiatric units. Inpatient admission was defined as a distinct encounter that included at least 1 calendar day on an inpatient unit. Blood-culture sets were defined by a unique laboratory accession number. Guidelines for paired blood-culture sets were defined as blood-culture sets taken within 1 hour of another blood culture set based on date and time of collection. Single-culture sets were blood-culture sets taken without another blood-culture set within a 12-hour period. Positive blood-culture sets were defined as blood-culture sets reported as (1) positive for an organism considered to be a pathogen or (2) positive for a common skin commensal in 1 of 1 (or more) blood-culture sets collected on separate date and time occasions using the NHSN common commensals list.^{[13](#page-5-0)} Contaminated blood cultures were defined as only 1 of 2, 3, or more blood culture sets collected in the same calendar day positive for a common skin commensal; they were not identified from a second (or more) blood-culture set on separate date and time occasions.

Statistical approach

Comparisons included χ^2 for categorical variables and t tests for continuous (if normal) variables and Wilcoxon for continuous (nonnormal) variables. A P value of $\langle .05 \rangle$ was considered significant, all statistical tests were 2-tailed, and all testing was completed using SAS version 9.4 software (SAS Institute, Cary, NC). The study was reviewed and approved by the Duke University institutional review board.

Results

Hospital size ranged from 247 to 977 beds. All hospitals were in the southeastern United States; 4 hospitals were classified as urban and 2 as rural (Supplementary Table [1](https://doi.org/10.1017/ice.2022.191) online). Also, 3 hospitals had oncology units and 2 had bone-marrow transplant units. The median hospital length of stay was 2 days (IQR, 1–4). In total, 111,520 blood-culture sets, 52,550 blood-culture events, 165,456 inpatient admissions, and 568,928 patient days were analyzed. Overall, the BCUR for all hospitals was 196.0 blood-culture sets per 1,000 patient days using the BCX definition, and 92.4 blood culture events per 1,000 patient days using the BCE definition (Fig. 1). The median number of blood-culture events per encounter was 1 (range, 1–31); 7% were single-culture events; 55% began in the ED; and 77% occurred in the first 3 hospital days (Table [1\)](#page-2-0). At the blood-culture set level, 7.7% of blood-culture sets were positive; 2.1% were likely contaminated; 5.9% of first blood-culture sets were collected after the initiation of antibiotics with a median of 7 hours (IQR, 1–42); and 30.2% of cultures were follow-up

Table 1. Blood Culture Event Data by Hospital

Variable	Hospital A. $(N = 20,883),$ No. (%)	Hospital B, $(N = 3,592)$, No. (%)	Hospital C. $(N = 3,954)$, No. (%)	Hospital D, $(N = 6,307)$, No. (%)	Hospital E. $(N = 8,606)$, No. (%)	Hospital F, $(N = 9,208),$ No. (%)	Overall, $(N = 52,550)$, No. (%)
Median blood-culture events per encounter (range)	$1(1-31)$	$1(1-5)$	$1(1-5)$	$1(1-6)$	$1(1-11)$	$1(1-6)$	$1(1-31)$
Single culture blood culture events	2,489(12)	220(6)	61(2)	231(4)	275(3)	318(3)	3,594(7)
Blood-culture events beginning in the emergency department	7,952 (38)	2,637(73)	2,434(62)	4,702 (75)	4,056 (47)	7,204 (78)	28,985 (55)
Blood-culture events in the first 3 hospital days	12,950 (62)	3,344(93)	3,647(92)	5,622(89)	6,401(74)	8,436 (82)	40,400 (77)

Table 2. Blood Culture Data by Hospital

cultures after a prior blood culture and initiation of antibiotics (Table 2). Of all positive blood-culture sets, 31.6% were positive for Staphylococcus aureus; 18.6% were positive for Escherichia coli; 7.8% were positive for Klebsiella pneumoniae; 5.6% were positive for Enterococcus faecalis; 4.4% were positive for Pseudomonas aeruginosa; and 31.9% were positive for other species.

Hospital-level analyses

The BCUR using the BCX definition varied between hospitals; the lowest occurred in hospital E and the highest in hospital C. Less extreme variation was seen using the BCE definition (Fig. [1](#page-1-0)). Most patients had a single blood-culture event per admission, which was similar between hospitals though there was a long outlier at hospital A (31 cultures in a single admission). The percentage of singleculture sets varied by hospital (range, 2%–12%). Notably, the high outlier hospital in BCUR (C) also had the lowest rate of single bloodculture sets. More than 50% of blood-culture events began in the ED in all but hospitals A and E (Table 1). Blood-culture positivity rates varied among study hospitals (range, 4.5%–9.0%) as well as the rate of contaminated cultures (range, 1.3%–3.2%). At the hospital level, the proportions of the 5 species most frequently identified in positive blood-culture sets were similar to those of the overall results (in descending order): S. aureus, E. coli, K. pneumoniae, E. faecalis, and P. aeruginosa. However, at hospital C, E. coli ranked number 1 followed by S. aureus. The proportion of first blood-culture sets ordered after the initiation of antibiotics was similar between hospitals (range, 3.5%–8.5%) except for a relatively high value at hospital E. The percentage of follow-up blood-culture sets collected after the initiation of antibiotics varied greatly between hospitals (range, 17.8%–40.7%) (Table 2).

Unit-level analyses

The highest BCURs occurred in intensive care units followed by oncology and transplant units, medical and surgical units, mixed acuity units, and labor and delivery units (Figs. [2](#page-3-0) and [3](#page-3-0)). This remained consistent overall. At hospital C, a high BCUR was noted in the labor and delivery unit, which upon investigation was a mislabeled medical-surgical unit (Fig. [2](#page-3-0)). The percentage of contaminated blood-culture sets among all blood cultures was the highest in the ED (2.8%), followed by intensive care units (1.5%), medical-surgical units (1.1%), oncology and transplant units (1.1%), mixed acuity units (1.1%), and labor and delivery units (0.6%). Among contamination events, most occurred in the ED (77%), followed by medical-surgical units (10%), intensive care units (9%), oncology and transplant units (3%), mixed acuity units (1%), and labor and delivery units (0.7%). The percentage of single culture-blood culture events was high in general oncology and hematology units (24%) and very high in stem-cell transplant units (60%) (Fig. [3\)](#page-3-0).

Time-based analyses

Overall, a higher number of BCEs occurred on Mondays and a lower number on weekends (Supplementary Fig. [2](https://doi.org/10.1017/ice.2022.191) online). However, when stratified, this pattern remained for ED blood cultures but not for non-ED units where blood cultures remained stable between days of the week. When observing BCURs by month, no seasonal patterns were observed (Supplementary Fig. [3](https://doi.org/10.1017/ice.2022.191)).

Discussion

In this study, we evaluated the pattern of blood-culture utilization using multiple metrics among a cohort of 6 hospitals to identify potential opportunities for diagnostic stewardship and to provide hospital comparisons that could contribute to hypothesis generation in future studies. Our analyses revealed distinct patterns that may highlight specific practice areas in which individual hospitals might focus improvement efforts toward optimizing when and how to obtain blood cultures. For example, the frequency of single blood-culture events was relatively high at 3 of 6 study hospitals, and especially in oncology and stem-cell units at hospital A. At hospital E, a larger proportion of blood cultures were ordered after antibiotic therapy initiation compared to other hospitals, which is known to reduce culture sensitivity.^{[14](#page-5-0)} For some hospitals,

Fig. 2. Blood-culture utilization rate by hospital and unit type. Note. NHSN units were condensed into 5 general labels for ease of visualization. *Indicates the mislabeled unit at hospital C as labor and delivery, which was actually being used for surgery overflow.

Fig. 3. Proportion of single culture-blood culture events by unit type.

most blood-culture events occurred in their higher-volume EDs, and these hospitals also had higher overall contamination rates. These findings demonstrate that hospital-level comparisons are helpful for identifying high-yield diagnostic stewardship targets and that the Eds may be a particular area for improvement.

Our results differed from the analysis by Chen et al¹⁵ of bloodculture utilization at an academic medical center. Using the BCX metrics, their study determined an overall BCUR of 307.7 sets per 1,000 patient days compared to our findings of 196.0 blood cultures per 1,000 patient days. This difference is likely due to the data of Chen et al including a much higher proportion of blood cultures taken from the oncology unit (25.9%) compared to our study (5.9%).[15](#page-5-0) This difference emphasizes the need to compare BCURs between hospitals to identify unique patterns targetable for antimicrobial stewardship or otherwise. However, our results were similar to the findings of Willems et al⁷ of 103–188 per 1,000 patient days at 5 Belgian hospitals.⁷

Additionally, our positivity and contamination rates, overall and at the hospital level, are similar to those of several previous studies, and they fell within expected ranges of 7%–9% and 2%–3%, respectively.1,3,8,9,[15](#page-5-0) Overall and at the hospital level, the proportions of species identified in positive blood-culture sets were similar to those reported in a previous study.^{[16](#page-5-0)} Several metrics used in this study, such as BCE and BCUR by month, are novel. Also, descriptive data regarding monthly BCURs have been limited to pediatrics in prior literature.[17](#page-5-0),[18](#page-5-0) To our knowledge, this study is the first descriptive, multicenter study to include analyses at the hospital level with comparisons that revealed practice patterns. We proposed a novel blood-culture utilization metric using blood-culture events instead of raw blood-culture sets to better differentiate single-culture events, which is discouraged as a practice due to reduced yield as well as difficulty in interpreting contaminants. For example, using both metrics allowed us to identify hospital C, which consistently used paired culture practices while having relatively high utilization rates.

Our study had several limitations. These analyses were completed on an existing data set from a previous study of antibiotic de-escalation and included 6 hospitals from the southeastern United States, which may not be generalizable to other practice settings. Also, we included ED blood cultures in the numerator without a corresponding patient day in the denominator, which made it more difficult to directly compare to previous studies and consensus statements. However, our data suggest that more opportunities for optimization of blood-culture use occurred in the ED, so excluding this practice area from analyses would limit the ability to evaluate the highest volume area of blood-culture use in the hospital. If not included in hospital-level rates, then ED-specific metrics (eg, BCXs per ED visit) and comparisons may provide an alternative method of evaluating this important practice area. Like any hospital comparisons, many potential factors (eg, case mix, specialty care) can influence blood-culture metrics, and we did not comprehensively investigate such factors because the aim of this pilot study was largely descriptive and our data set was not large enough. Additionally, we were unable to assess whether cultures were drawn from catheters or peripherally. Lastly, pediatric patients were excluded from our analyses due to limited pediatric data in our cohort. We believe that dedicated study of pediatric blood-culture utilization and hospital comparisons would be necessary because blood-culture ordering practices and standards differ considerably from adults.

In conclusion, blood-culture utilization varied by hospital and unit and was heavily influenced by ED culture volumes and practices. Comparisons among hospitals may assist in identifying opportunities to optimize blood-culture ordering and collection practices as well as targets for stewardship teams. Additionally, hospital comparisons allow stewards to acknowledge differences in blood-culture utilization targets due to disparate patient populations and hospital characteristics. Once opportunities are identified, stewards can then act based on previous recommendations (eg, reducing single blood cultures and determining true positives vs contamination).^{[19,20](#page-5-0)} These comparisons also highlight variation in blood-culture order practices, which has implications for clinical surveillance methods that rely on blood-culture orders as an objective marker of suspected infection. Our study also successfully provided hospital comparisons that did and will continue to lead to hypothesis generation for future studies. Future studies should prioritize larger, multicenter comparisons and should work toward better understanding how comparative blood-culture utilization data may be useful for identifying and tracking practice improvements.

Supplementary material. To view supplementary material for this article, please visit <https://doi.org/10.1017/ice.2022.191>

Acknowledgments.

Financial support. This work was funded by the Centers for Disease Control and Prevention: Duke–UNC Prevention Epicenter Program for Prevention of Healthcare-Associated Infections (grant no. 1U54-CK000483).

Conflicts of interest. All authors report no conflicts of interest relevant to this article.

References

- 1. Miller JM, Binnicker MJ, Campbell S, et al. A guide to utilization of the microbiology laboratory for diagnosis of infectious diseases: 2018 update by the Infectious Diseases Society of America and the American Society for Microbiology. Clin Infect Dis 2018;67:e1–e94.
- 2. Fabre V, Carroll KC, Cosgrove SE. Blood-culture utilization in the hospital setting: a call for diagnostic stewardship. J Clin Microbiol 2021; July:1–32.
- 3. Fabre V, Sharara SL, Salinas AB, Carroll KC, Desai S, Cosgrove SE. Does this patient need blood cultures? A scoping review of indications for blood cultures in adult nonneutropenic inpatients. Clin Infect Dis 2020;71: 1339–1347.
- 4. Centers for Disease Control and Prevention. Hospital Toolkit for Adult Sepsis Surveillance. 2018 (May).
- 5. Centers for Medicare and Medicaid Services. Specifications Manual for National Hospital Inpatient Quality Measures. The Joint Commission website. [https://www.jointcommission.org/-/media/tjc/documents/](https://www.jointcommission.org/-/media/tjc/documents/measurement/specification-manuals/hiqr_specsman_july2019_v5_6.pdf) [measurement/specification-manuals/hiqr_specsman_july2019_v5_6.pdf](https://www.jointcommission.org/-/media/tjc/documents/measurement/specification-manuals/hiqr_specsman_july2019_v5_6.pdf). Published July 2019. Accessed July 21, 2022.
- 6. Fabre V, Klein E, Salinas AB, et al. A diagnostic stewardship intervention to improve blood culture use among adult nonneutropenic inpatients: The DISTRIBUTE study. J Clin Microbiol 2020;58:1–8.
- 7. Willems E, Smismans A, Cartuyvels R, et al. The preanalytical optimization of blood cultures: a review and the clinical importance of benchmarking in 5 Belgian hospitals. Diagn Microbiol Infect Dis 2012;73:1–8.
- 8. Baron EJ, Weinstein MP, Dunne, W M Jr, Yagupsky P, Welch DF, Wilson DM. Cumitech 1C, Blood Cultures IV. Coordinating ed., Baron EJ. Washington, D.C.: ASM Press; 2005.
- 9. Bates DW, Cook EF, Goldman L, Lee TH. Predicting bacteremia in hospitalized patients. A prospectively validated model. Ann Intern Med
1990;113:495–500.
The DETOURS Trial: de-escalating empiric treatment: opting out of Rx for
selected patients with suspected sepsis—opt-out protocol tri 1990;113:495–500.
- 10. The DETOURS Trial: de-escalating empiric treatment: opting out of Rx for Trials website. <https://clinicaltrials.gov/ct2/show/NCT03517007>. Accessed July 21, 2022.
- 11. National Healthcare Safety Network. CDC locations and descriptions and instructions for mapping patient care locations table of contents instructions for mapping patient care locations in NHSN step 1: define the acuity level for the location. Centers for Disease Control and Prevention website. [https://www.cdc.gov/nhsn/pdfs/pscmanual/15locationsdescriptions_](https://www.cdc.gov/nhsn/pdfs/pscmanual/15locationsdescriptions_current.pdf) [current.pdf](https://www.cdc.gov/nhsn/pdfs/pscmanual/15locationsdescriptions_current.pdf). Published January 2021. Accessed July 26, 2022.
- 12. National Healthcare Safety Network. Multidrug-resistant organism & Clostridioides difficile infection (MDRO/CDI) module. Centers for Disease Control and Prevention website. [https://www.cdc.gov/nhsn/psc/](https://www.cdc.gov/nhsn/psc/cdiff/index.html) [cdiff/index.html](https://www.cdc.gov/nhsn/psc/cdiff/index.html). Published January 2021. Accessed July 26, 2022.
- 13. National Healthcare Safety Network. Bloodstream infection event (centralline–associated bloodstream infection and non–central-line–associated bloodstream infection) table of contents. Centers for Disease Control and Prevention website. [https://www.cdc.gov/nhsn/pdfs/pscmanual/4psc_](https://www.cdc.gov/nhsn/pdfs/pscmanual/4psc_clabscurrent.pdf) [clabscurrent.pdf](https://www.cdc.gov/nhsn/pdfs/pscmanual/4psc_clabscurrent.pdf). Published January 2021. Accessed January 27, 2021.
- 14. Cheng MP, Stenstrom R, Paquette K, Yansouni C, Sweet D. Blood-culture results before and after antimicrobial administration. Ann Intern Med 2020;172:440–441.
- 15. Chen AI, Bilker WB, Hamilton KW, O'Donnell JA, Nachamkin I. Bloodculture utilization at an academic hospital: addressing a gap in benchmarking. Infect Control Hosp Epidemiol 2018;39:1353–1359.
- 16. Diekema DJ, Hsueh PR, Mendes RE, et al. The microbiology of bloodstream infection: 20-year trends from the SENTRY antimicrobial surveillance program. Antimicrob Agents Chemother 2019;63: e00355–19.
- 17. Liu H, Herzig CTA, Dick AW, et al. Impact of state reporting laws on central-line–associated bloodstream infection rates in US adult intensive care units. Health Serv Res 2017;52:1079–1098.
- 18. Woods-Hill CZ, Fackler J, McMillan KN, et al. Association of a clinical practice guideline with blood culture use in critically ill children. JAMA Pediatr 2017;171:157–164.
- 19. Lamy B, Dargère S, Arendrup MC, Parienti JJ, Tattevin P. How to optimize the use of blood cultures for the diagnosis of bloodstream infections? A state of the art. Front Microbiol 2016;7.
- 20. von Doern G, Carroll KC, Diekema DJ, et al. Practical guidance for clinical microbiology laboratories: a comprehensive update on the problem of blood culture contamination and a discussion of methods for addressing the problem. Clin Microbiol Rev 2019; 33:e00009–19.